These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10194556)

  • 1. Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.
    Sava G; Clerici K; Capozzi I; Cocchietto M; Gagliardi R; Alessio E; Mestroni G; Perbellini A
    Anticancer Drugs; 1999 Jan; 10(1):129-38. PubMed ID: 10194556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.
    Sava G; Capozzi I; Clerici K; Gagliardi G; Alessio E; Mestroni G
    Clin Exp Metastasis; 1998 May; 16(4):371-9. PubMed ID: 9626816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
    Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
    J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
    Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
    Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice.
    Sava G; Gagliardi R; Cocchietto M; Clerici K; Capozzi I; Marrella M; Alessio E; Mestroni G; Milanino R
    Pathol Oncol Res; 1998; 4(1):30-6. PubMed ID: 9555118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
    Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
    Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors.
    Sava G; Pacor S; Mestroni G; Alessio E
    Anticancer Drugs; 1992 Feb; 3(1):25-31. PubMed ID: 1623212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.
    Cocchietto M; Zorzet S; Sorc A; Sava G
    Invest New Drugs; 2003 Feb; 21(1):55-62. PubMed ID: 12795530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties.
    Sava G; Pacor S; Mestroni G; Alessio E
    Clin Exp Metastasis; 1992 Jul; 10(4):273-80. PubMed ID: 1617835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation.
    Alessio E; Iengo E; Zorzet S; Bergamo A; Coluccia M; Boccarelli A; Sava G
    J Inorg Biochem; 2000 Apr; 79(1-4):173-7. PubMed ID: 10830863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
    Magnarin M; Bergamo A; Carotenuto ME; Zorzet S; Sava G
    Anticancer Res; 2000; 20(5A):2939-44. PubMed ID: 11062704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of residual metastases with Na[trans-RuCl4 (DMSO)lm] and ruthenium uptake by tumor cells.
    Bergamo A; Cocchietto M; Capozzi I; Mestroni G; Alessio E; Sava G
    Anticancer Drugs; 1996 Aug; 7(6):697-702. PubMed ID: 8913439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.
    Gagliardi R; Sava G; Pacor S; Mestroni G; Alessio E
    Clin Exp Metastasis; 1994 Mar; 12(2):93-100. PubMed ID: 8306532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
    Sava G; Bergamo A; Zorzet S; Gava B; Casarsa C; Cocchietto M; Furlani A; Scarcia V; Serli B; Iengo E; Alessio E; Mestroni G
    Eur J Cancer; 2002 Feb; 38(3):427-35. PubMed ID: 11818210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
    Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
    Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of a murine metastatic cell line and preliminary test of sensitivity to the anti-metastasis agent NAMI-A.
    Pacor S; Vadori M; Vita F; Bacac M; Soranzo MR; Zabucchi G; Sava G
    Anticancer Res; 2001; 21(4A):2523-30. PubMed ID: 11724317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry.
    Capozzi I; Clerici K; Cocchietto M; Salerno G; Bergamo A; Sava G
    Chem Biol Interact; 1998 May; 113(1):51-64. PubMed ID: 9630847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment.
    Pacor S; Zorzet S; Cocchietto M; Bacac M; Vadori M; Turrin C; Gava B; Castellarin A; Sava G
    J Pharmacol Exp Ther; 2004 Aug; 310(2):737-44. PubMed ID: 15075381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
    Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.